{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:34:24Z","timestamp":1784543664672,"version":"3.55.0"},"reference-count":51,"publisher":"American Association for Cancer Research (AACR)","issue":"3","funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Patients with multiple myeloma have a compromised immune system, due to both the disease and antimyeloma therapies, and may therefore be particularly susceptible to COVID-19. Here, we report outcomes and risk factors for serious disease in patients with multiple myeloma treated at five large academic centers in New York City in the spring of 2020, during which it was a global epicenter of the SARS-CoV-2 pandemic. Of 100 patients with multiple myeloma (male 58%; median age 68) diagnosed with COVID-19, 75 were admitted; of these, 13 patients (17%) were placed on invasive mechanical ventilation, and 22 patients (29%) expired. Of the 25 nonadmitted patients, 4 were asymptomatic. There was a higher risk of adverse outcome (intensive care unit admission, mechanical ventilation, or death) in Hispanics\/Latinos (n = 21), OR = 4.7 (95% confidence interval, 1.3\u201316.7), and African American Blacks (n = 33), OR = 3.5 (1.1\u201311.5), as compared with White patients (n = 36). Patients who met the adverse combined endpoint had overall higher levels of inflammatory markers and cytokine activation. None of the other studied risk factors were significantly associated (P &amp;gt; 0.05) with adverse outcome: hypertension (n = 56), OR = 2.2 (0.9\u20135.4); diabetes (n = 18), OR = 0.9 (0.3\u20132.9); age &amp;gt;65 years (n = 63), OR = 1.8 (0.7\u20134.6); high-dose melphalan with autologous stem cell transplant &amp;lt;12 months (n = 7), OR = 0.9 (0.2\u20135.4); and immunoglobulin G &amp;lt;650 mg\/dL (n = 42), OR = 0.9 (0.3\u20132.2). In this largest cohort to date of patients with multiple myeloma and COVID-19, we found the case fatality rate to be 29% among hospitalized patients and that race\/ethnicity was the most significant risk factor for adverse outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Patients with multiple myeloma are immunocompromised, raising the question whether they are at higher risk of severe COVID-19 disease. In this large case series on COVID-19 in patients with multiple myeloma, we report 29% mortality rates among hospitalized patients and identify race\/ethnicity as the most significant risk factor for severe outcome.<\/jats:p>\n                    <jats:p>See related video:\u2008https:\/\/vimeo.com\/486246183\/559a80cfae<\/jats:p>\n                    <jats:p>See related commentary by Munshi and Anderson, p. 218.<\/jats:p>\n                    <jats:p>This article is highlighted in the In This Issue feature, p. 215<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-20-0102","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T22:45:40Z","timestamp":1596149140000},"page":"234-243","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers"],"prefix":"10.1158","volume":"1","author":[{"given":"Malin","family":"Hultcrantz","sequence":"first","affiliation":[{"name":"1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[{"name":"2Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3576-9106","authenticated-orcid":false,"given":"Cara A.","family":"Rosenbaum","sequence":"additional","affiliation":[{"name":"3Center for Myeloma, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhwani","family":"Patel","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-7587","authenticated-orcid":false,"given":"Eric L.","family":"Smith","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Korde","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney X.","family":"Lu","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8419-1091","authenticated-orcid":false,"given":"Urvi A.","family":"Shah","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Lesokhin","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Hassoun","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlyn","family":"Tan","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Maura","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriy","family":"Derkach","sequence":"additional","affiliation":[{"name":"4Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8638-9365","authenticated-orcid":false,"given":"Benjamin","family":"Diamond","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Rossi","sequence":"additional","affiliation":[{"name":"3Center for Myeloma, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger N.","family":"Pearse","sequence":"additional","affiliation":[{"name":"3Center for Myeloma, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepu","family":"Madduri","sequence":"additional","affiliation":[{"name":"2Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"2Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kaminetzky","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Multiple Myeloma Research Perlmutter Cancer Center, NYU Langone Health, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J.","family":"Braunstein","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Multiple Myeloma Research Perlmutter Cancer Center, NYU Langone Health, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gordillo","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Oncology, Columbia University Medical Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Reshef","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Oncology, Columbia University Medical Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Taur","sequence":"additional","affiliation":[{"name":"7Infectious Diseases, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"8Department of Medicine, Joan and Sanford Weill Medical College of Cornell University, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith E.","family":"Davies","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Multiple Myeloma Research Perlmutter Cancer Center, NYU Langone Health, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[{"name":"2Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Niesvizky","sequence":"additional","affiliation":[{"name":"3Center for Myeloma, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Oncology, Columbia University Medical Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4271-6360","authenticated-orcid":false,"given":"Gareth J.","family":"Morgan","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Multiple Myeloma Research Perlmutter Cancer Center, NYU Langone Health, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2020,11,4]]},"reference":[{"key":"2022060217073043600_bib1","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"2022060217073043600_bib2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1158\/2159-8290.CD-20-0422","article-title":"Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak","volume":"10","author":"Dai","year":"2020","journal-title":"Cancer Discov"},{"key":"2022060217073043600_bib3","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"2022060217073043600_bib4","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1056\/NEJMc2009787","article-title":"Large-vessel stroke as a presenting feature of Covid-19 in the young","volume":"382","author":"Oxley","year":"2020","journal-title":"N Engl J Med"},{"key":"2022060217073043600_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol"},{"key":"2022060217073043600_bib6","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/s41375-020-0836-7","article-title":"COVID-19 in persons with haematological cancers","volume":"34","author":"He","year":"2020","journal-title":"Leukemia"},{"key":"2022060217073043600_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-0979-0","article-title":"Determinants of COVID-19 disease severity in patients with cancer","author":"Robilotti","year":"2020","journal-title":"Nat Med"},{"key":"2022060217073043600_bib8","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.annonc.2020.03.296","article-title":"Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China","volume":"31","author":"Zhang","year":"2020","journal-title":"Ann Oncol"},{"key":"2022060217073043600_bib9","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1111\/bjh.16874","article-title":"Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy","volume":"190","author":"Cook","year":"2020","journal-title":"Br J Haematol"},{"key":"2022060217073043600_bib10","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1158\/2159-8290.CD-20-0516","article-title":"Case fatality rate of cancer patients with COVID-19 in a New York hospital system","volume":"10","author":"Mehta","year":"2020","journal-title":"Cancer Discov"},{"key":"2022060217073043600_bib11","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet"},{"key":"2022060217073043600_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-020-0931-4","article-title":"COVID-19 outcomes in patients with hematologic disease","author":"Malard","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"2022060217073043600_bib13","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.annonc.2020.04.006","article-title":"Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City","volume":"31","author":"Miyashita","year":"2020","journal-title":"Ann Oncol"},{"key":"2022060217073043600_bib14","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"key":"2022060217073043600_bib15","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/s41375-018-0163-4","article-title":"Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials","volume":"32","author":"Heaney","year":"2018","journal-title":"Leukemia"},{"key":"2022060217073043600_bib16","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.6004\/jnccn.2019.0049","article-title":"NCCN Guidelines Insights: multiple myeloma, version 1.2020","volume":"17","author":"Kumar","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2022060217073043600_bib17","first-page":"832","article-title":"Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications","volume":"85","author":"Steingrimsdottir","year":"2000","journal-title":"Haematologica"},{"key":"2022060217073043600_bib18","doi-asserted-by":"crossref","first-page":"m1985","DOI":"10.1136\/bmj.m1985","article-title":"Features of 20 133 UK patients in hospital with Covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study","volume":"369","author":"Docherty","year":"2020","journal-title":"BMJ"},{"key":"2022060217073043600_bib19","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMc2010419","article-title":"Clinical characteristics of Covid-19 in New York City","volume":"382","author":"Goyal","year":"2020","journal-title":"N Engl J Med"},{"key":"2022060217073043600_bib20","article-title":"Case fatality risk of the first pandemic wave of novel coronavirus disease 2019 (COVID-19) in China","author":"Deng","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022060217073043600_bib21","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMsa2011686","article-title":"Hospitalization and mortality among black patients and white patients with Covid-19","volume":"382","author":"Price-Haywood","year":"2020","journal-title":"N Engl J Med"},{"key":"2022060217073043600_bib22","first-page":"48:23\u20139.e4","article-title":"Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York","author":"Rosenberg","year":"2020","journal-title":"Ann Epidemiol"},{"key":"2022060217073043600_bib23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"2022060217073043600_bib24","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"key":"2022060217073043600_bib25","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"key":"2022060217073043600_bib26","doi-asserted-by":"crossref","first-page":"e0211927","DOI":"10.1371\/journal.pone.0211927","article-title":"Infectious complications and NK cell depletion following daratumumab treatment of multiple myeloma","volume":"14","author":"Nahi","year":"2019","journal-title":"PLoS One"},{"key":"2022060217073043600_bib27","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"2022060217073043600_bib28","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s11899-017-0397-7","article-title":"Novel immunotherapies for multiple myeloma","volume":"12","author":"D'Agostino","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"2022060217073043600_bib29","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe","volume":"23","author":"Fermand","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022060217073043600_bib30","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"2022060217073043600_bib31","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41375-020-0876-z","article-title":"Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)","volume":"34","author":"Terpos","year":"2020","journal-title":"Leukemia"},{"key":"2022060217073043600_bib32","doi-asserted-by":"crossref","DOI":"10.1159\/000507690","article-title":"Multiple myeloma in the time of COVID-19","author":"Al Saleh","year":"2020","journal-title":"Acta Haematol"},{"key":"2022060217073043600_bib33","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1016\/S2352-3026(20)30124-1","article-title":"Management of patients with multiple myeloma during the COVID-19 pandemic","volume":"7","author":"Malard","year":"2020","journal-title":"Lancet Haematol"},{"key":"2022060217073043600_bib34","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa2006100","article-title":"Spread of SARS-CoV-2 in the Icelandic population","volume":"382","author":"Gudbjartsson","year":"2020","journal-title":"N Engl J Med"},{"key":"2022060217073043600_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jama.2020.6130","article-title":"Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China","volume":"323","author":"Pan","year":"2020","journal-title":"JAMA"},{"key":"2022060217073043600_bib36","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.chom.2020.04.009","article-title":"Complex immune dysregulation in COVID-19 patients with severe respiratory failure","volume":"27","author":"Giamarellos-Bourboulis","year":"2020","journal-title":"Cell Host Microbe"},{"key":"2022060217073043600_bib37","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.thromres.2020.04.041","article-title":"Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb Res"},{"key":"2022060217073043600_bib38","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1016\/j.jacc.2020.04.032","article-title":"Inpatient use of ambulatory telemetry monitors for COVID-19 patients treated with hydroxychloroquine and\/or azithromycin","volume":"75","author":"Chang","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022060217073043600_bib39","doi-asserted-by":"crossref","first-page":"101663","DOI":"10.1016\/j.tmaid.2020.101663","article-title":"Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study","volume":"34","author":"Gautret","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"2022060217073043600_bib40","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N Engl J Med"},{"key":"2022060217073043600_bib41","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/S0140-6736(20)31324-6","article-title":"RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis","volume":"395","author":"Mehra","year":"2020","journal-title":"Lancet"},{"key":"2022060217073043600_bib42","article-title":"Dexamethasone in hospitalized patients with Covid-19 - preliminary report","author":"RECOVERY Collaborative Group","year":"2020","journal-title":"N Engl J Med"},{"key":"2022060217073043600_bib43","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"2022060217073043600_bib44","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/bloodadvances.2020001907","article-title":"First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"key":"2022060217073043600_bib45","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"2022060217073043600_bib46","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"key":"2022060217073043600_bib47","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1111\/bjh.16787","article-title":"Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma","volume":"190","author":"Chaidos","year":"2020","journal-title":"Br J Haematol"},{"key":"2022060217073043600_bib48","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19-preliminary report","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"2022060217073043600_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial","volume":"324","author":"Li","year":"2020","journal-title":"JAMA"},{"key":"2022060217073043600_bib50","doi-asserted-by":"crossref","first-page":"eabd0110","DOI":"10.1126\/sciimmunol.abd0110","article-title":"Inhibition of Bruton tyrosine kinase in patients with severe COVID-19","volume":"5","author":"Roschewski","year":"2020","journal-title":"Sci Immunol"},{"key":"2022060217073043600_bib51","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-020-00934-x","article-title":"A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward.","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"}],"updated-by":[{"DOI":"10.1158\/2643-3230.bcd-20-0160","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000}}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/1\/3\/234\/3041697\/234.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/1\/3\/234\/3041697\/234.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T03:20:54Z","timestamp":1667618454000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/1\/3\/234\/62\/COVID-19-Infections-and-Clinical-Outcomes-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,11,4]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-20-0102","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.22542939.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.6550092.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1101\/2020.06.09.20126516","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22542939","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.6550092","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,1]]}}}